THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 122 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $345 | -51.0% | 40 | -41.2% | 0.00% | – |
| Q2 2023 | $704 | +70300.0% | 68 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 68 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -99.9% | 68 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -98.1% | 68 | -99.0% | 0.00% | – |
| Q3 2021 | $52,000 | -33.3% | 7,000 | +84.2% | 0.00% | – |
| Q1 2021 | $78,000 | +14.7% | 3,800 | 0.0% | 0.00% | – |
| Q4 2020 | $68,000 | +23.6% | 3,800 | +3.1% | 0.00% | – |
| Q3 2020 | $55,000 | +511.1% | 3,687 | +738.0% | 0.00% | – |
| Q2 2020 | $9,000 | -92.6% | 440 | -91.6% | 0.00% | -100.0% |
| Q1 2020 | $121,000 | -13.6% | 5,250 | -3.0% | 0.00% | 0.0% |
| Q4 2019 | $140,000 | -15.7% | 5,410 | -36.4% | 0.00% | 0.0% |
| Q3 2019 | $166,000 | -9.3% | 8,500 | -24.1% | 0.00% | -50.0% |
| Q2 2019 | $183,000 | -28.0% | 11,199 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $254,000 | – | 11,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |